Boehringer Ingelheim has secured the option to license a cystic fibrosis gene therapy. Boehringer Ingelheim has exercised the option to license a cystic fibrosis gene therapy in a collaboration with the UK 's Advanced Cancer Gene Therapy Consortium and Oxford BioMedica ( OXB ) to develop an inhaled , lentiviral vector - based treatment . Boehringer will provide funding , along with research and development , to move the therapy through preclinical studies , while OXB will provide expertise in lentiviral - based vector production . Boehringer 's option to acquire the global rights to the therapy can be exercised during the research and development process .
Boehringer Ingelheim has exercised the option to license a cystic fibrosis gene therapy in a collaboration with the UK 's Advanced Cancer Gene Therapy Consortium and Oxford BioMedica ( OXB ) to develop an inhaled , lentiviral vector - based treatment . Boehringer will provide funding , along with research and development , to move the therapy through preclinical studies , while OXB will provide expertise in lentiviral - based vector production . Boehringer 's option to acquire the global rights to the therapy can be exercised during the research and development process .